Ramipril H Mibe 5 mg/25 mg tablete
| Name | Ramipril H Mibe 5 mg/25 mg tablete |
|---|---|
| Former Name | Ramipril H Farmal 5 mg/25 mg tablete |
| Marketing Authorisation Number | HR-H-249692705 |
| Active Substance | ramipril hidroklorotiazid |
| Composition | jedna tableta sadrži 5 mg ramiprila i 25 mg hidroklorotiazida |
| Pharmaceutical Form | tableta |
| Manufacturer | mibe GmbH Arzneimittel, Brehna, Njemačka |
| Marketing Authorisation Holder | Mibe Pharmaceuticals d.o.o., Zavrtnica 17, Zagreb, Hrvatska |
| Marketing Authorisation Date | 31.01.2020 |
| MA Period of Validity | unlimited |
| MA Revocation Date | 15.09.2023* |
| Classification Number | UP/I-530-09/15-02/190 |
| Registration Number | 381-12-01/70-20-27 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | C09BA05 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od nemelanomskog raka kože povezanog s primjenom hidroklorotiazida | 17.10.2018 | Alkaloid, Belupo, Berlin-Chemie Menarini, Boehringer Ingelheim International, Farmal, Genericon, Pharma, Jadran Galenski laboratorij, Krka - farma, Merck, Merck Sharp & Dohme, Novartis, PharmaSwiss, Pliva, Sandoz, sanofi-aventis i Stada |
